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Cancer cells’ growth in three-dimensional (3D) architectures promotes resistance to drugs, cytokines, or irradiation. We investigated
effects of 3D culture as compared to monolayers (2D) on melanoma cells’ recognition by tumour-associated antigen (TAA)-specific
HLA-A*0201-restricted cytotoxic T-lymphocytes (CTL). Culture of HBL, D10 (both HLA-A*0201þ, TAAþ) and NA8 (HLA-
A*0201þ, TAA ) melanoma cells on polyHEMA-coated plates, resulted in generation of 3D multicellular tumour spheroids
(MCTS). Interferon-gamma (IFN-g) production by HLA-A*0201-restricted Melan-A/MART-127–35 or gp100280–288-specific CTL
clones served as immunorecognition marker. Co-culture with melanoma MCTS, resulted in defective TAA recognition by CTL as
compared to 2D as witnessed by decreased IFN-g production and decreased Fas Ligand, perforin and granzyme B gene expression. A
multiplicity of mechanisms were potentially involved. First, MCTS per se limit CTL capacity of recognising HLA class I restricted
antigens by reducing exposed cell surfaces. Second, expression of melanoma differentiation antigens is downregulated in MCTS.
Third, expression of HLA class I molecules can be downregulated in melanoma MCTS, possibly due to decreased interferon-
regulating factor-1 gene expression. Fourth, lactic acid production is increased in MCTS, as compared to 2D. These data suggest that
melanoma cells growing in 3D, even in the absence of immune selection, feature characteristics capable of dramatically inhibiting TAA
recognition by specific CTL.
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The identification of a large number of tumour-associated antigens
(TAA) (Renkvist et al, 2001) has raised hopes of taking advantage
of the enormous increase of knowledge stemming from basic
immunology research to ameliorate the prognosis of neoplastic
diseases by active antigen-specific immunotherapy, that is, by
vaccination. Trials based on diverse immunisation procedures
have been performed in different types of cancer and promising
data have been reported (Nestle et al, 1998; Rosenberg et al, 1998;
Thurner et al, 1999; Bedrosian et al, 2003; Slingluff et al, 2003).
Indeed, immune responses specific for TAA can be generated
relatively easily ‘in vitro’ and ‘in vivo’, as detectable by phenotypic
and functional assays. However, only in a minority of patients
showing evidence of successful immunisation, clinical responses
are also detectable.
Interestingly, experimental murine models indicate that tumour
cells in suspension, regardless of their numbers, are frequently
unable to produce life-threatening cancer outgrowth, as opposed
to solid tumour fragments (Ochsenbein et al, 2001), while inducing
specific immune responses. Thus, proliferation in structured
architectures appears to represent a pre-requisite for cancer
development.
In the human experimental setting, cytotoxicity assays or the
functional monitoring of clinical immunotherapy trials are usually
performed by utilising, as targets, cell lines, frequently of lympho/
myeloid origin, expressing appropriate HLA alleles upon pulsing
with specific peptides. Tumour-associated antigens recognition
may eventually be confirmed by using, as additional targets,
tumour cell lines expressing specific HLA determinants and
transcribing relevant TAA-encoding genes. Current protocols
typically imply the admixture of effector and target cells pelleted
together in culture wells. The lack of correlation between data
obtained ‘in vitro’ with these technologies and clinical data
suggests that this model might not adequately account for critical
aspects of the interaction between immunocompetent cells and
cancers.
Three-dimensional (3D) culture models have been developed in
the past decade, aiming at exploring radio or chemoresistance of
tumour cells in ‘in vitro’ assays more closely related to ‘in vivo’
conditions than standard monolayers (Sutherland, 1988). In
particular, multicellular tumour spheroids (MTCS) have been
suggested to represent accurately early events of avascular tumour
growth (Desoize and Jardillier, 2000).
Multicellular tumour spheroids remind in vivo cancers in their
capacity to develop necrotic areas far from nutrient and oxygen
supplies. Furthermore, cells cultured in MCTS are also similar to
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ssolid tumours in their proliferation dynamics (Gorlach et al, 1994),
since at difference with monolayer cultures, they fit the Gompertz
equation, classically used to quantitatively evaluate neoplastic
growth (Chignola et al, 2000).
Three-dimensional growth of tumour cells in vitro has been
shown to affect antigen recognition by specific cytotoxic T-
lymphocytes (CTL). For instance, tumour infiltrating lymphocytes
capable of killing autologous bladder tumour cells in 2D, failed
to recognise targets when cultured in 3D (Dangles et al, 2002).
Similarly, a CTL clone specific for a mutated a-actinin-4 peptide
expressed by autologous lung cancer cells recognised poorly
targets growing in MCTS, possibly due to a downregulation of
HSP70 expression (Dangles-Marie et al, 2003).
Regarding melanoma, a cancer frequently targeted in clinical
immunotherapy trials, we recently showed that the architecture of
tumour cell growth determines specific gene expression profiles, of
potentially high functional significance. Furthermore, we showed
that the recognition of a melanoma TAA by a specific CTL clone
was impaired when target cells were cultured in MCTS (Ghosh
et al, 2005a,b).
These data suggest that antigen-specific functional activities of
CTL might be significantly altered in the presence of tumour cells
growing in multilayered architectures. Underlying mechanisms,
however, are still poorly investigated.
In this work, we explored the molecular bases of impaired
recognition by CTL specific for TAA of melanoma cells cultured in
three-dimensional architectures. We report that a multiplicity of
mechanisms ranging from structural hindrances to downregula-
tion of antigen and HLA expression to lactic acid overproduction
concurrently limit the susceptibility of melanoma cells cultured in
MCTS to the attack by TAA-specific CTL.
MATERIALS AND METHODS
Cell cultures
NA8 (courtesy of Dr Jotereau, Nantes, France), HBL and D10 cell
lines (courtesy of Dr A Eberle, Basel, Switzerland) derive from
metastatic melanoma and have widely been used in tumour
immunology studies in the recent past (Gervois et al, 1996; Oertli
et al, 2002; Zajac et al, 2003). They are all HLA-A*0201þ.
However, whereas HBL and D10 express typical melanoma
differentiation TAA (Certa et al, 2001; Renkvist et al, 2001), NA8
does not (Certa et al, 2001).
Cell lines were routinely passaged in conventional 2D cultures in
RPMI 1640 supplemented with 10mM HEPES buffer, 1mM sodium
pyruvate, 2mM non-essential amino acids, 2mM glutamine,
100mgml
 1 Kanamycin (Invitrogen, Carlsbad, CA, USA) and
10% heat-inactivated FCS, hereafter referred to as complete
medium.
Multicellular tumour spheroids were prepared in U-bottom 96-
well plates previously coated with 50mgml
 1 poly-2-hydroxyethyl-
methacrylate (polyHEMA, Sigma, St Louis, MO, USA) solution,
preventing cell binding as described (Folkman and Moscona,
1978). Cells proliferation was measured by the alamarBluet Assay
(Serotec, Oxford, UK) (Hamid et al, 2004).
Cytotoxic T-lymphocyte clones were generated from peripheral
blood CD8þ T cells of patients undergoing active antigen specific
immunotherapy in the context of specific clinical trials, as
described previously (Oertli et al, 2002; Zajac et al, 2003). Briefly,
cells from bulk cultures showing evidence of antigen-specific
cytotoxic activity, as detectable by
51Cr release assays, were cloned
in 60-well Terasaki plates (Nunc, Glostrup, Denmark) at 0.3 cells
per well in 20ml volumes in the presence of 10000 irradiated
allogenic PBMC/well, in RPMI 1640 supplemented with 10mM
HEPES buffer, 1mM sodium pyruvate, 2mM non-essential
amino acids, 2mM glutamine, 100mgml
 1 Kanamycin (Invitrogen,
Carlsbad, CA, USA) and 5% pooled human serum (RPMI-HS), to
which rIL-2 (200Uml
 1) and purified phytohemagglutinin (PHA,
0.5mgml
 1, Remel, Dartford, UK) were added. After 14 days, wells
where cell growth was microscopically detectable were expanded in
RPMI-HS supplemented with 100Uml
 1 rIL-2 and screened for
antigen-specific cytotoxic activity by
51Cr release assay. Cytotoxic
T-lymphocyte clones were maintained in RPMI-HS supplemented
with 100Uml
 1 rIL-2 and restimulated periodically with PHA in
the presence of irradiated allogenic PBMC. All assays reported here
were performed at least 1 week after re-stimulation.
Confocal microscopy
Cells were stained with PKH26 red fluorescent cell linker (Sigma-
Aldrich, St Louis, MO, USA) following suppliers instructions, and
cultured on polyHEMA-coated plates for 3 days to form 30000
cells MCTS. Total CD8þ T cells from healthy donors and CTL
clones specific for HLA-A*0201-restricted Melan-A/MART-127–35
epitope were stained with CFSE (molecular Probes, Eugene, OR,
USA). Cells (E:T ratio¼2.5:1) were added to each MCTS and
co-cultured for 1 day. Confocal images for the evaluation of total
CD8þ T cells or CTL infiltration in NA8 and HBL MCTS,
respectively, were obtained using a laser-scanning confocal
microscope Zeiss LSM 510 (Carl Zeiss Microimaging Inc., Thorn-
wood, NY, USA).
Antigen recognition assays
Interferon-gamma production was used as antigen recognition
assay. As target/stimulator cells, we used melanoma cells cultured
in 2D or in MCTS. Cytotoxic T-lymphocyte specific for Melan-A/
MART-1 or gp100 and used as effectors, were co-cultured with
target cells at 2.5:1 ratio for 24h. When indicated, assays were
performed by using, as targets, HBL cells previously cultured in
monolayers in the presence of 0–20mM lactic acid (Sigma-Aldrich,
St Louis, MO, USA) for 3 days. In all cases, supernatants were
collected and IFN-g secretion was measured by using human IFN-g
BD OptEIAt ELISA Set (BD Biosciences, Franklin Lakes, NJ, USA).
All samples were measured in triplicates.
Quantification of gene expression by quantitative real-time
PCR
Cells were collected at the indicated time points and washed in
PBS. Total RNA was extracted using the RNeasy
s Mini Kit
protocol (Qiagen, Basel, Switzerland), treated by Deoxyribonu-
clease I (DNase I) (Invitrogen, Carlsbad, CA, USA), and reverse
transcribed by using the Moloney Murine Leukemia Virus Reverse
Transcriptase (M-MLV RT, Invitrogen, Carlsbad, CA, USA).
Quantitative real-time PCR were performed in the ABI prismt
7700 sequence detection system, using the TaqMan
s Universal
PCR Master Mix, No AmpErase
s UNG (both from Applied
Biosystems, Foster City, CA, USA).
Specific gene expression was quantitated by using the 2 DDCT,
method (Winer et al, 1999; Livak and Schmittgen, 2001; Malec
et al, 2004; Nieman et al, 2004). Normalisation of gene expression
was performed using GAPDH as reference gene and data were
expressed as ratio to reference samples.
Primers and probes
Oncostatin M (OSM), interferon-regulating factor-1 (IRF-1), and
microphtalmia-associated transcription factor (MITF) primers and
probes are from pre-developed assays (Assays-on-Demand, Gene
Expression Products (Applied Biosystems, Foster City, CA, USA)).
Oligonucleotide primers and probes for c-myc, Melan-A/MART-1,
gp100, and tyrosinase were generated using appropriate software
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s(Primer Expresst, Applied Biosystems, Foster City, CA, USA)
from sequences obtained from the NCBI gene bank.
Furthermore, a number of sequences for primers and probes
were derived from existing literature, as indicated below.
Flow cytometry analysis
HLA class I expression was quantified using FITC-conjugated mAb
specific for HLA-A*0201 or a similar reagent specific for a non-
polymorphic determinant of HLA class I heavy chain (PharMingen,
San Diego, CA, USA). The HBL, D10 or NA8 cells cultured in 2D
were collected using Trypsin-EDTA (Invitrogen, Carlsbad, CA,
USA) after 3 days culture. Accordingly, MCTS obtained after 3
days culture were disrupted by 5min trypsinisation at 371C. Cells
were then incubated with specific or control mAbs, for 45min at
41C in the dark, washed twice in cold PBS, fixed 1min in
paraformaldehyde 1%, re-suspended in 200ml PBS, and analysed
on a FACSCalibur
s cytometer (Becton Dickinson, Franklin Lakes,
NJ, USA).
Lactic acid measurement
Quantification of lactic acid production by melanoma cells was
performed after 3-day cultures in 2D or in 3D (30000 cell density),
using as immobilised enzyme biosensor, YSI 2300 STAT Glucose
and Lactate analyser (YSI, Yellow Springs, OH, USA), following the
suppliers’ protocols.
Statistical analysis
Statistical analysis software SPSS (Version 14.0, SPSS Inc., Chicago,
IL, USA) was used for statistical analyses. Mann–Whitney U-tests
were used to calculate asymptotic significance between two
independent samples. All reported P-values were two-tailed and
were considered to be statistically significant at Pp0.05.
RESULTS
Morphological characterisation and growth pattern of
melanoma spheroids
Melanoma cells were routinely maintained in monolayer (2D)
cultures in complete medium. Upon culture on 96-well plates
coated with polyHEMA preventing cell attachment (Folkman and
Moscona, 1978), they formed 3D aggregates. Multicellular tumour
spheroids consisting of 5000 or 30000 cells showed 0.3–0.8mm
diameter (Figure 1A).
Consistent with previous results by our group (Ghosh et al,
2005a,b), proliferation kinetics of cells cultured in 2D or 3D were
dramatically different. Data reported in Figure 1B regarding D10
melanoma cell line as representative example indicate that
proliferation in 2D cultures reached a plateau within 5 days,
whereas, in contrast, no major modifications in cell numbers were
detectable in MCTS within 20 days of culture.
Morphology of the interaction between TAA-specific CTL
and melanoma cells cultured in spheroids
First, we investigated the morphology of the interaction between
melanoma cells cultured in 3D and immunocompetent cells,
focusing on immature Dendritic Cells (iDC) capable of antigen
uptake and processing and, most importantly, on CD8þ T cells,
largely responsible for tumour-specific cytotoxic activities.
NA8 (HLA-A*0201þ, Melan-A/MART-1-) or HBL (HLA-
A*0201þ, Melan-A/MART-1þ) cells cultured as MCTS, iDC,
total CD8þ T cells, and HLA-A*0201-restricted Melan-A/
MART-127–35-specific CTL clones were labelled with different
fluorochromes. NA8 cells were co-cultured with either iDC or total
CD8þ T cells. Furthermore, HBL cells were co-incubated for 24h
together with TAA-specific CTL clones. Confocal microscopy was
then used to verify the consequences of this interaction at
morphological level. Typically, iDC, CD8þ T cells in general
and TAA-specific CTL in particular were unable to penetrate in
deep the 3D architecture of MCTS, but rather tended to remain on
their surfaces (Figure 2). These pictures closely reminded the ‘non-
brisk’ infiltration of melanoma by T cells, as frequently observed
in clinical tumour specimens (Mihm Jr et al, 1996; Bernsen et al,
2004).
CTL clones display a differential capacity of recognising
endogenously processed TAA in melanoma cells cultured
in monolayers or in MCTS
Lack of MCTS infiltration by TAA-specific CTL hinted at a possible
defective killing of tumour cells cultured in spheroids. Indeed,
growth in 3D architectures was suggested previously to prevent the
recognition of TAA by specific effector T cells (Dangles et al, 2002,
2003; Ghosh et al, 2005a). We intended to verify if similar events
occur when melanoma cells are cultured in MCTS and the
eventually underlying molecular mechanisms.
Percentages of TAA-specific T cells ‘ex vivo’ are extremely low,
and usually do not exceed 0.5% of total CD8þ T cells, at best
(Seiter et al, 2002). Thus, to perform our studies in controlled
conditions, we again resorted to the use of antigen-specific cloned
T cells as effectors. Importantly, CTL clones are far more efficient
in this respect than T cells freshly obtained from peripheral blood
(Pittet et al, 2003). As tumour cells cultured in 3D are unfit to serve
as targets for
51Cr release assays, because washing steps required
after labelling disrupt cell aggregates, we turned to IFN-g
production by antigen-specific T cells following interaction with
GAPDH (Martin et al, 2001):
Fwd ATGGGGAAGGTGAAGGTCG
Rev TAAAAGCAGCCCTGGTGACC
Probe FAM-CGCCCAATACGACCAAATCCGTTGAC-TAMRA
FasL (Stylianou et al, 2002):
Fwd CCATTTAACAGGCAAGTCCAACT
Rev TCACTCCAGAAAGCAGGACAATT
Probe FAM-TCACTCCAGAAAGCAGGACAATT-TAMRA
Perforin (Miles et al, 2002):
Fwd TTCTACAGTTTCCATGTGGTACACACT
Rev GTGGGTGCCGTAGTTGGAGATA
Probe FAM-ACCCAGCCCGCCTACCTCAGGC-TAMRA
Granzyme B (Mocellin et al, 2003):
Fwd TCCTAAGAACTTCTCCAACGACACT
Rev GCACAGCTCTGGTCCGCT
Probe FAM-TGCTACTGCAGCTGGAGAGAAAGGCC-TAMRA
Melan-A/MART-1:
Fwd TCTATGGTTACCCCAAGAAGGG
Rev GATCACTGTCAGGATGCCGA
Probe FAM-ACGGCTGAAGAGGCCGCTGGGAT-TAMRA
gp100:
Fwd TCCCCCTGGATTGTCTTCTG
Rev CTCAAATGCATCCCCCTCA
Probe FAM-CCCTGGACATTGTCCAGGGTATTGAAAGTGA-TAMRA
Tyrosinase:
Fwd TTTGCCTGAGTTTGACCCAAT
Rev AGAGGCATCCGCTATCCCA
Probe FAM-TAGAAATACACTGGAAGGATTTGCTAGTCCACTTACTA-
TAMRA
c-myc:
Fwd GCCACGTCTCCACACATCAG
Rev TCTTGGCAGCAGGATAGTCCTT
Probe FAM-ACGCAGCGCCTCCCTCCACTC-TAMRA
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stargets expressing appropriate TAA and restriction determinants,
as a classical alternative antigen recognition assay (Butterfield
et al, 1999; Pelfrey et al, 2000).
HBL and D10 HLA-A*0201þ melanoma cells expressing Melan-
A/MART-1 and gp100 differentiation TAA cultured in 2D or 3D
were used to stimulate IFN-g production by previously char-
acterised specific CTL clones (Zajac et al, 2003). NA8 cells
(HLA-A*0201þ, TAA ) were used as negative controls.
As expected, HBL and D10 cells cultured in 2D induced high
IFN-g production in gp100280–288 or Melan-A/MART-127–35-specific
CTL clones. In sharp contrast, considerably lower amounts of
cytokine were produced if CTL were stimulated with spheroids
of 30000 HBL or D10 target cells following 3-day culture in
3D. Similar results were obtained in independent experiments
performed by using different gp100280–288 or Melan-A/MART-127–35
specific, HLA-A*0201 restricted CTL clones, at different E:T
ratios. Representative data are reported in Figure 3A.
These differences tended to disappear when CTL were
challenged with spheroids containing p2000 cells (not shown).
These data suggest that polyHEMA ‘per se’ is not toxic to CTL.
Elicitation of CTL functions relies on the expression of an array
of components of their lytic machinery. For instance, CTL may kill
through Fas pathway (Ostergaard et al, 1987; Rouvier et al, 1993),
and granzymes entering target cells (Froelich et al, 1996; Jans et al,
3D NA8 30000+iDC
3D NA8 30000+Total CD8+T cells
3D HBL 30000+Melan-A/MART-127–35 specific CTL clone
Figure 2 ‘Non-brisk’ infiltration of melanoma MCTS by iDC, total
CD8þ T cells and antigen-specific CTL. NA8 and HBL cells were stained
with PKH26 red fluorochrome and cultured on polyHEMA-coated plates
for 3 days to form 30000 cells MCTS. Immature DC, total CD8þ T cells
from a healthy donor and a CTL clone specific for HLA-A*0201-restricted
Melan-A/MART-127–35 epitope were labelled with CFSE. Cells were added
at a 2.5:1 ratio to each MCTS and co-cultured for 24h. Immature DC,
total CD8þ T cells and TAA-specific CTL infiltration in NA8 and HBL
MCTS, respectively, were analysed by confocal microscopy.
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Figure 1 Generation and characterisation of MCTS of melanoma cells.
(A) In all, 5000 or 30000 melanoma cells (NA8, HBL, and D10) were
cultured on polyHEMA-coated plates to prevent cell attachment for 3 days,
resulting in the formation of MTCS of an average diameter of 300–800mm.
(B) D10 cells proliferation was evaluated by alamarBluet Assay (Serotec,
Oxford, UK). Divergent kinetics were detectable for D10 cells cultured in
monolayer (2D) or MCTS (3D). Similar results were observed for NA8
(Ghosh et al, 2005b) and HBL cells (Ghosh et al, 2005a).
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Figure 3 Functions of TAA-specific CTL are impaired when target melanoma cells are cultured in MCTS. (A) Interferon-gamma secretion by CTL clones
upon stimulation with HBL, D10, or NA8 cells cultured in 2D or in MCTS. Cytotoxic T-lymphocyte clones specific for HLA-A*0201-restricted gp100280–288
or Melan-A/MART-127–35 epitopes and displaying corresponding tetramer binding profiles (right panels) were co-incubated for 24h at 2.5:1 E:T ratio in the
presence of similar numbers of HBL or D10 melanoma cells (HLA-A*0201þ,gp100þ,Melan-A/MART-1þ), cultured in 2D (&)o ri n3 D( ’). Interferon-
gamma secretion was measured by ELISA in culture supernatants. Data are reported as average of triplicate measurements. Error bars represent the
standard deviation of the mean concentration of triplicate cultures. (B) The FasL, perforin, and granzyme B gene expression in CTL stimulated by 2D or 3D
cultured HBL. Cells from a CTL clone specific for HLA-A*0201-restricted Melan-A/MART-127–35 epitope were co-cultured for 24h at 2.5:1 E:T ratio in the
presence of HBL melanoma cells cultured in 2D (&)o ri n3 D( ’). Total cellular RNA was extracted and reverse transcribed. FasL, perforin, and granzyme
B gene expression were analysed by quantitative real-time PCR. Data were expressed as ratio to cells incubated in the presence of melanoma cells cultured
in 2D. (C) Interferon-gamma secretion by CTL cultured with HBL cells from intact or disrupted MCTS. Cells from a CTL clone specific for HLA-A*0201-
restricted Melan-A/MART-127–35 epitope were stimulated for 24h at 1:1 E:T ratio in the presence of HBL melanoma cells cultured in 2D (&), in 3D (’)
or following MCTS disruption ( ). Interferon-gamma secretion was measured by ELISA in culture supernatants. Data are reported as average of triplicate
measurements. Error bars represent the standard deviation of the mean concentration of triplicate cultures.
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s1998; Pinkoski et al, 1998; Edwards et al, 1999) may rapidly induce
their DNA fragmentation-based apoptosis (Heusel et al, 1994;
Shresta et al, 1995). Furthermore, perforin in the CTL granules
plays a pivotal role in granule-mediated killing (Helgason et al,
1992; Kagi et al, 1994; Kojima et al, 1994; Lowin et al, 1994). Thus,
we also assessed CTL functions by evaluating FasL, granzyme B,
and perforin gene expression in CTL co-cultured with melanoma
target cells growing in 2D or in MCTS (Figure 3B). As expected,
interaction with targets Melan-A/MART-127–35þHLA-A*0201þ
cultured in 2D resulted in the expression of FasL, granzyme B, and
perforin genes in antigen-specific CTL. However, the expression of
these genes was significantly lower when effector cells were
stimulated by MCTS.
These data indicated that antigen recognition by CTL can be
impaired if target cells are cultured in 3D, rather than in
monolayers. A possible explanation for this observation could be
offered by mere structural considerations: culture in spheroids
may provide an overall smaller cell surface accessible to CTL
attack, as compared to monolayers, resulting in decreased
activation of effector cells. To address this issue, HBL cells were
cultured in MCTS and subsequently disaggregated. The resulting
cell suspensions were used to stimulate antigen-specific CTL.
Melanoma cells from freshly disrupted spheroids indeed induced
IFN-g secretion in Melan-A/MART-127–35-specific CTL clones to
levels intermediate between those induced by 2D or 3D cultured
HBL (Figure 3C). These results indicate that the observed
impairment of antigen recognition by CTL is at least in part due
to the smaller cell surface accessible to effectors, but it cannot be
exclusively ascribed to structural hindrances.
Melan-A/MART-1, gp100 and tyrosinase expression in HBL
and D10 cells cultured in 2D and 3D
Previous work suggests that high cell density in monolayer
cultures could affect TAA expression (Ramirez-Montagut et al,
2000). In an attempt to clarify molecular mechanisms underlying
our observations, we addressed antigen expression in target cells.
Thus, we comparatively explored the expression not only of
Melan-A/MART-1 and gp100 but also of tyrosinase genes,
encoding differentiation antigens widely used in active specific
immunotherapy (Zajac et al, 2003) in HBL and D10 melanoma
cells cultured in either MCTS or conventional 2D conditions. NA8
cells (Certa et al, 2001) were used as negative controls (Figure 4A).
Quantitative real-time PCR analysis revealed that HBL and D10
cells cultured in MCTS display a significantly lower (p40%)
expression of Melan-A/MART-1, gp100 and tyrosinase differentia-
tion TAA as compared to similar numbers of cells cultured in
2D conditions. Similar profiles were obtained using 18S as
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Figure 4 Tumour-associated antigens expression in melanoma cells cultured in 2D or in MCTS. (A) Melan-A/MART-1, gp100, and tyrosinase gene
expression in melanoma cells cultured in 2D or in MCTS at different cell densities. HBL and D10 cells were cultured for 3 days in monolayer or in 3D at
different cell densities (5000 and 30000 cells). Total cellular RNA was extracted, reverse transcribed. Melan-A/MART-1, gp100, and Tyrosinase gene
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TAA expression, were used as negative control. (B) Microphtalmia-associated transcription factor gene expression in melanoma cells cultured in 2D or in
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shouse-keeping gene. Importantly, this downmodulation was visible
in 3-day-old spheroids, well before the appearance of inner necrotic
cores on days 10–12 (Walenta et al, 1990; Santini and Rainaldi,
1999; Ghosh et al, 2005b). Most interestingly, it was clearly related
to cell density. Indeed, the highest downregulation of the
expression of genes encoding differentiation TAA was detectable
in spheroids containing 30000 melanoma cells, whereas milder
effects were recorded in 3D structures including 5000 tumour cells.
Interestingly, HBL and D10 cells from aggregates disrupted by
vigorous pipetting and subsequently cultured in monolayers could
not recover baseline (2D) TAA gene expression before 3–5 days
(data not shown).
As hypoxia may represent an early event in inner MCTS layers,
leading, as reviewed previously (Douglas and Haddad, 2003; Zhou
et al, 2006), to typical gene expression profiles, we investigated
whether it could play a role in the downregulation of the
expression of melanoma differentiation antigens observed in
spheroids. Monolayer cultures of D10 and HBL cell lines were
incubated in low (5%) pO2 for 3 days and the expression of the
genes under investigation was subsequently assessed. In no case we
observed a significant downmodulation of melanoma TAA in cells
cultured in hypoxic conditions (data not shown).
Taken together, these data indicated that the architecture of
cultures might regulate the expression of melanoma differentiation
antigens.
It has been recently reported that OSM, produced by melanoma
cells actively downregulates Melan-A/MART-1 mRNA transcrip-
tion inducing antigen silencing in tumour cells (Durda et al, 2003).
On the other hand, Melan-A/MART-1 and gp100 gene expression
have been shown to be transcriptionally controlled by MITF
(Du et al, 2003), the master regulator of melanocytic differentiation.
We explored comparatively the expression of the genes
encoding these soluble factors potentially involved in the
modulation of antigen expression in HBL, D10, and NA8
melanoma cells cultured in either MCTS or conventional 2D
conditions (Figure 4B). While OSM gene expression was not
detectable (data not shown), MITF gene expression was down-
regulated in the three cell lines under investigation, when cultured
in MCTS as compared to 2D. These effects appeared to be cell
density dependent. Furthermore, they did not result from an
overall decrease of metabolic activities of cell cultured in 3D.
Indeed, our own oligonucleotide chip hybridisation experiments
(Ghosh et al, 2005b) clearly indicated that upregulation of a
number of genes takes place in the melanoma cells under
investigation when cultured in 3D.
Modulation of HLA class I expression in spheroids of
different sizes
The expression of HLA class I molecules and, in particular, of
HLA-A*0201, the allele restricting the immunodominant CTL
response to the gp100 and Melan-A/MART-1 epitopes under
investigation was also evaluated in melanoma cells cultured in
MCTS as compared to 2D. Figure 5A reports data from one
representative experiment out of three performed. HBL MCTS
(30000 cells per spheroids) displayed a marked (4fivefold)
decrease in HLA-A*0201 expression at the protein level, as
compared to 2D cultures. This downmodulation was not allele
specific, as similar results were obtained by using a mAb specific
for a monomorphic epitope on HLA class I heavy chain. This
reduction also appeared to be cell density dependent. In D10
MCTS a significant (Xtwofold) decrease in HLA molecules
expression, as compared to 2D cultures, was also observed.
Notably, however, this was not a constant finding in all the cell
lines under investigation. For instance, NA8 melanoma cells (HLA-
A*0201þ, TAA ) displayed a divergent HLA modulation pattern
as compared to HBL and D10. Indeed, when cultured in MCTS,
NA8 showed significant (Xtwofold) increases in HLA-A*0201 and
overall HLA class I expression, especially at a cell density of 5000
cells per spheroids.
HLA class I gene expression is regulated by transcription factors
of the IRF family (Girdlestone et al, 1993), whereas c-myc has been
shown to downregulate HLA class I expression in human
melanoma (Versteeg et al, 1988).
Consistent with the HLA expression data observed at the protein
level, IRF-1 gene expression was also cell density dependently
downregulated in HBL and D10 cultured in MCTS as compared to
2D. Accordingly, IRF-1 gene expression was upregulated in NA8
MCTS in comparison with cells cultured in monolayers.
On the other hand, surprisingly, c-myc expression was
significantly downregulated in D10 and HBL spheroids, as
compared to cells cultured in monolayer, but it was unaffected
in NA8 spheroids (Figure 5B).
Role of lactic acid in the defective recognition by TAA-
specific CTL of tumour cells cultured in spheroid
Cancer cells are known to be characterised by high production of
lactic acid under aerobic conditions (Warburg, 1956; Kim and
Dang, 2006). Recently, it has been shown that production of
lactic acid is enhanced in tumour cells cultured in spheroids, as
compared to monolayers (Gottfried et al, 2005). Most importantly,
lactic acid, at the concentrations produced by tumour cells in these
culture conditions inhibits the proliferation of antigen specific CTL
lines co-cultured with autologous dendritic cells in the presence of
antigenic peptides (Gottfried et al, 2005). Prompted by this report,
we evaluated the production of lactic acid by the melanoma cell
lines under investigation and its eventual role in the defective
antigen recognition by specific CTL.
A 3-day culture of HBL cells in MCTS induced a 460% increase
in their lactic acid production (Figure 6A), as compared to
monolayer cultures. We then performed our antigen recognition
assays by using as targets HBL melanoma cells cultured in 2D
in the absence or in the presence of graded concentrations of
exogenous lactic acid (Sigma-Aldrich, St Louis, MO, USA).
As expected, target cells cultured in 2D-induced antigen-
stimulated IFN-g production by a Melan-a/MART-127–35 HLA-
A*0201-restricted CTL clone to an extent significantly higher than
cells cultured in MCTS. However, addition of exogenous lactic acid
to target cell monolayers resulted in a trend towards decreasing
IFN-g production. In particular, in the presence of 20mM lactic
acid, target cell monolayers induced CTL responses not signifi-
cantly different from those triggered by target cells cultured in
MCTS in the absence of exogenous lactic acid (Figure 6B).
DISCUSSION
The past decade has witnessed an unprecedented wave of cancer
immunotherapy trials, prompted by the identification of large
numbers of TAA and by major advances in basic immunology.
Most of these efforts have targeted metastatic melanoma. A large
majority of published reports suggest that a variety of different
vaccination procedures are capable of inducing TAA-specific CTL
in high percentages of immunised patients. However, clinical
responses are detectable only in a minority of them. These data
underline that even in the presence of specific immune response,
tumours may be relatively insensitive to its effects.
Molecular mechanisms underlying the discrepancy between
immunological and clinical responsiveness to active antigen-
specific immunotherapy have been investigated by several groups.
Tumour escape from CTL recognition has been attributed to
downregulation of TAA or HLA class I molecules expression
(Marincola et al, 2000) possibly resulting from the selection of
resistant variants in neoplastic cell populations exposed to
immunological pressure. However, this mechanism, whose in vivo
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Figure 5 HLA class I expression in melanoma cells cultured in 2D or in MCTS. (A) Flow cytometric analysis of HLA-A*0201 and HLA Class I expression
in melanoma cells cultured in 2D or in MCTS at different cell densities. The HBL, D10, and NA8 cells were cultured for 7 days in 2D or 3D at the indicated
cell densities. Cells were then harvested, and aggregates were disrupted by vigorous pipetting and trypsinisation. Cells were stained either with control
antibodies (thin lines) or with mAbs recognising HLA-A*0201 or a monomorphic epitope on HLA class I heavy chains (bold lines). Relevant mean
fluorescence intensities, reported in individual histograms, were calculated by subtracting values deriving from isotype control staining from experimental
values. (B) Expression of c-myc and IRF-1 genes in melanoma cells cultured in 2D or in MCTS at different cell densities. HBL, D10, or NA8 cells were
cultured for 3 days in 2D (&)o ri n3 D( : 5000 cells – ’: 30000 cells). Gene expression was analysed by quantitative real-time PCR and results are
expressed as ratio to specific gene expression, as observed in the corresponding 2D sample used as reference.
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srelevance is debated, might indirectly support the concept of a
clinical efficacy of CTL induction, whose evidence is mostly
missing (Marincola et al, 2003).
More recently, the discrepancy between induction of TAA-
specific immune responses and clinical responsiveness has
also been attributed to CTL defects. TAA-specific T cells sampled
ex vivo from tumour metastases have been shown to be quiescent
(Monsurro et al, 2003, 2004; Zippelius et al, 2004), and
characterised by an impaired capacity to produce IFN-g upon
antigenic challenge. Still unclear, however, is the role of the
tumour cells, if any, in inducing such state.
These reports urge the development of novel in vitro models
utilising human cells and permitting controlled investigations of
the interaction between tumour cells and the immune system.
Data from different groups, including ours, indicate that culture
of tumour cells in 3D structures modulates their gene expression
profiles and decreases their susceptibility to the immune-mediated
CTL attack, although still unclear are the underlying molecular
mechanisms (Ghosh et al, 2005a,b).
Here, we show that TAA-specific CTL are unable to penetrate in
deep the 3D architecture of MCTS, closely reminding the ‘non-
brisk’ infiltration of melanoma by T cells observed in clinical
cancer tissues (Mihm et al, 1996; Bernsen et al, 2004). This lack of
infiltration suggested a possible defective killing of tumour cells
cultured in spheroids. Indeed, our study shows that lower amounts
of IFN-g are produced by CTL stimulated by melanoma cells
cultured in MCTS as compared to those cultured with tumour cell
monolayers. The concept of impaired elicitation of CTL functions
was reinforced by decreases in FasL, granzyme B, and perforin
gene expression in antigen-specific CTL when cultured with MCTS
as compared with their counterparts cultured in 2D.
Our data indicate that a multiplicity of mechanisms concur in
decreasing the susceptibility of melanoma cells cultured in MCTS to
the effects of antigen-specific CTL, as compared with cell monolayers.
First, 3D structures per se, limit the capacity of effector cells in
recognising HLA class I restricted antigens possibly by merely
reducing the cell surface exposed to CTL. This mechanism, however,
is only partially responsible for the impaired antigen recognition, as
CTL cultured with melanoma cells from disrupted MCTS secreted
IFN-g at a level intermediate between 2D and MCTS.
Second, the expression of melanoma differentiation antigens is
downregulated in tumour cells cultured in 3D as compared with
monolayers. In our hands, this is neither related to hypoxia nor to
increased OSM gene expression but rather to a decreased MITF
gene expression and to the high cell concentrations elicited by
culture in MCTS.
Third, the surface expression of HLA class I molecules can be
downregulated in melanoma cells cultured in 3D, as compared
with their counterparts in 2D.
These features have been detected relatively frequently in
clinical melanoma specimen. Their occurrence has been attributed
to the outgrowth of cancer cells characterised by low expression of
TAA and/or restricting HLA class I determinants following
exposure of tumours to immunoselective pressures (Marincola
et al, 2000). However, our data suggest that a low expression of
HLA class I molecules and at least of melanoma differentiation
antigens in tumours, could be inherent in their 3D growth, even in
the absence of an exogenous immune pressure.
Fourth and finally, lactic acid production by melanoma cells is
increased if they are cultured in MCTS, as compared with
monolayer cultures, and lactic acid significantly inhibits TAA-
triggered IFN-g production by specific CTL. Consistent with
previous reports (Gottfried et al, 2006), these effects appear to be
mediated by functional inhibition of effector cells, as no down-
regulation of TAA expression is detectable in melanoma cells
cultured in these conditions. Interestingly, lactic acid produced
within melanoma and prostate cancer MCTS has also been shown
to impair the phenotypic and functional maturation of infiltrating
dendritic cells thereby inhibiting their antigen-presenting capacity
(Gottfried et al, 2006).
Most importantly, none of these mechanisms alone is able to
entirely account for the inhibition of antigen recognition by
specific CTL, detectable upon culture in the presence of melanoma
cells cultured in 3D, as opposed to 2D. Their combination,
however, elicits powerful inhibitory effects.
We are fully aware that culture of melanoma cell lines in 3D
might only partially reflect the complexity of solid tumours
developing in vivo. However, the clear discrepancy between data
obtained by applying techniques of current use for the in vitro
detection of antitumour responses and clinical evidence urges the
development of alternative experimental models. Multicellular
tumour spheroids may then qualify as technology of choice for the
screening not only of novel drugs, but also of immune-mediated
therapeutic procedures.
Further research is warranted to explore in this controlled in
vitro model the consequences on effector cells of their interaction
with tumour cells growing in 3D architectures, as opposed to
growing in monolayers or in suspension.
Importantly, providing a molecular background to widespread
clinical experience, our data suggest that the effectiveness of
antitumour immune response may largely depend not only on
affinity and functional capacities of effector cells, but also on the
structural characteristics of the growth of cancer cells, rather than
on their mere numbers, and strongly support the use of active
antigen-specific immunotherapies in minimal residual disease
states.
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Figure 6 Lactic acid production by tumour cells cultured in different
conditions and its role in antigen recognition by CTL. (A) Lactic acid
production by melanoma cells cultured in 2D or in 3D. The HBL cells were
cultured in standard monolayers or in MCTS (30000 cells) for 3 days.
Supernatants were then harvested and their lactic acid content was
measured as described in ‘Materials and Methods’. (B) Effects of lactic acid
on antigen recognition by CTL. Cytotoxic T-lymphocyte from a MelanA/
MART-127–35-specific HLA-A*0201 restricted clone were co-incubated
with HBL melanoma cells cultured in 2D (&)o r3 D( ’), as indicated, in
the presence of lactic acid at the indicated concentrations.
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